Effects of autologous platelet-rich plasma on implantation and pregnancy in repeated implantation failure: A pilot study

Leila Nazari M.D., Saghar Salehpour M.D., Sedighe Hoseini M.D., Shahrzad Zadehmodarres M.D., Ladan Ajori M.D.

Department of Obstetrics and Gynecology, Preventive Gynecology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Corresponding Author: Leila Nazari, Department of Obstetrics and Gynecology, IVF Center, Taleghani Hospital, Velenjak St., Chamran Highway, Tehran, Iran. Tel: (+98) 9123164282 Email: nazari@sbmu.ac.ir

Received: 22 August 2016 Accepted: 28 September 2016

Abstract

Background: Repeated implantation failure (RIF) is a major challenge in reproductive medicine and despite several methods that have been described for management, there is little consensus on the most effective one.

Objective: This study was conducted to evaluate the effectiveness of platelet-rich plasma in improvement of pregnancy rate in RIF patients.

Materials and Methods: Twenty women with a history of RIF who were candidates for frozen-thawed embryo transfer were recruited in this study. Intrauterine infusion of 0.5 ml of platelet-rich plasma that contained platelet 4-5 times more than peripheral blood sample was performed 48 hrs before blastocyst transfer.

Results: Eighteen participants were pregnant with one early miscarriage and one molar pregnancy. Sixteen clinical pregnancies were recorded and their pregnancies are ongoing.

Conclusion: According to this study, it seems that platelet-rich plasma is effective in improvement of pregnancy outcome in RIF patients.

Key words: Platelet-rich plasma, Implantation, Fertilization in Vitro, Pregnancy rate, Repeated implantation failure.

Introduction

Repeated implantation failure (RIF) is defined as failure to conceive following several embryo transfers in in vitro fertilization (IVF) cycles. There are no standard criteria for RIF description. According to European Society of Human Reproduction and Embryology consortium, RIF is defined as the absence of gestational sac on ultrasound at 5 wks or more after embryo transfer (ET) following 3 ET with high-quality embryos or after transfer of 10 or more embryos in multiple transfers (1-5). Numerous factors are involved in process of implantation including embryo quality, endometrial receptivity and immunological factors (6-8).

Several methods have performed for RIF management but there is little consensus on the most effective one. Blastocyst transfer, preimplantation genetic screening (PGS), assisted hatching, co-culture system, sequential transfer, hysteroscopy, endometrial scratching, salpingectomy for tubal disease, extra number embryo transfer, natural cycle, oocyte donation, intra-tubal ET, immune therapy and endometrial receptivity array (ERA) have been used but there is not any proved evidence in these treatments (9-12).

Recently, intrauterine infusion of platelet-rich plasma (PRP) is described to promote endometrial growth and receptivity. PRP is prepared from fresh whole blood that contained several growth factors and cytokines including fibroblast growth factor (FGF), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), insulin-like growth factor I, II (IGF-I, II), connective tissue growth factor (CTGF) and interleukin 8 (IL-8). PRP has been investigated as a therapeutic approach for several medical disorders including nerve injury, ocular epithelial defects, alopecia, cardiac muscle injury, osteoarthritis, and tendinitis. Despite the wide use of PRP in several fields in medicine, it’s efficacy in obstetrics and gynecology is limited (13-18).

We designed the present study to investigate whether intrauterine infusion of
PRP could improve pregnancy outcome in women with RIF.

Materials and methods

Study design
This was a single arm preliminary study of an RCT (registered at Iranian Registry of Clinical Trials: IRCT2016072229027N1) which conducted in IVF center, Taleghani Hospital, Tehran, Iran. The study was approved by ethical committee of Shahid Beheshti University of Medical Sciences (SBMU). All participants signed an informed written consent.

Thirty-two women who failed to conceive after 3 or more ET with high-quality embryos who were candidates for frozen-thawed embryo transfer (FET) were assessed for eligibility to enter the study from March to June 2016. Twelve women were excluded for different reasons; 20 were included in the study (Figure 1). The inclusion criteria were age below 40 yrs, body mass index (BMI) below 30 kg/m². The exclusion criteria were hematological and immunological disorders, hormonal disorders, chromosomal and genetic abnormalities and uterine abnormalities (acquired or congenital).

The hysteroscopic examination was performed before the cycle if it was not previously done. Laboratory evaluation of thrombophilia, antiphospholipid antibodies, hormonal disorders, hematological and immunological disorders in women and karyotype of couples were performed. All participants underwent FET cycle and hormone replacement therapy was performed for endometrial preparation as a same route: estradiol valerate (Aburaihan Co., Tehran, Iran) 6 mg/d was started from 2nd or 3rd day of mensural cycle and it was increased to 8 mg/d if endometrial thickness did not reach at least 8 mm.

During the cycle whenever the endometrial thickness was more than 8 mm, progesterone suppository (Cyclogest; Actavis, UK limited, England) 400 mg twice daily was started. Good quality blastocysts (Grade A or B according to embryologic scoring) transferred for all of the participants. Intrauterine infusion of PRP was done 48 hrs before ET. PRP was prepared from autologous blood and it was made by using two steps centrifuge process. Estradiol valerate and progesterone supplementation were continued for 2 wks after ET and if the serum Beta-Human Chorionic Gonadotropin (β-HCG) was positive hormone supplementations were continued until 12 wks of gestation. All Blastocyst transfers were performed under ultrasound guidance by one expert gynecologist with infertility fellowship. ET was performed according to American Society for Reproductive Medicine (ASRM) guidelines 2013 (Two or three embryos for each participant). On PRP infusion day, 17.5 ml of peripheral venous blood was drawn into a syringe that contains 2.5 ml of Acid Citrate A Anticoagulant solution (Arya Mabna Tashkhis, Iran) and centrifuged immediately at 1200 rpm for 12 min to separate red blood cells, then plasma was centrifuged again at 3300 rpm for 7 min to obtain PRP that contained platelet 4-5 times more than peripheral blood. 0.5 ml of PRP was infused into the uterine cavity with IUI catheter (Takwin, Iran). The previous cycle of each participant served as its own control.

Outcome assessment
Chemical pregnancy and clinical pregnancy was determined by positive serum β-HCG, 2 wks after ET and presence of fetal heart beat in transvaginal ultrasound 5 wks after ET.

Results
A total of 20 participants with RIF history were entered into this study. All of them were able to complete the study and their data were analyzed. Table I provides baseline characteristics summary. Uterine cavity abnormalities were not detected before starting the cycles. Seven women had a history of hysteroscopic surgery due to septum, Asherman’s syndrome and submucosal myoma. Participants had a history of failed previous ET attempts between 3-7 and their mean age was 33.4±5.7 years. Eighteen participants were pregnant with one early miscarriage and one molar pregnancy. Sixteen clinical pregnancies were recorded and their pregnancies are ongoing.

| Table I. Patients’ characteristics |
|----------------------------------|
| Age (years)* | 33.4 ± 5.7 |
| BMI (Kg/m²)* | 26.3 ± 3.6 |
| Etiology of Infertility** |   |
| Male Factor | 12 (60) |
| Female Factor |   |
| Anovulation | 5 (19) |
| DOR | 7 (35) |
| Tubal Factor | 3 (15) |
| Endometriosis | 2 (10) |
| Mixed (MF + FF) (%) | 9 (45) |
| Previous failed ET Cycles (no) (Min-Max) | 3-7 |

* Data presented as mean±SD. ** Data presented as n (%)
Discussion

Despite expanding experience in advanced reproductive technologies and great improvement in infertility treatment, implantation failure is one of the major challenges (8, 20-22). The receptive endometrium is the main factor for implantation and pregnancy. Even in the cases of replacement of chromosomally normal embryos, confirmed by PGS, successful implantation and pregnancy are not reassuring (2). In a normal menstrual cycle in human, endometrium becomes receptive during the mid-secretory phase around days 19-23 that is described as window of implantation. During this period, cytokines, growth factors, prostaglandins, and adhesion molecules are expressed and inconsistency of these proteins could impair implantation and pregnancy. Sak and co-workers investigated that expression of growth factors in the endometrium of women with RIF history is less than normal fertile women (21, 23, 24).

According to this hypothesis local infusion of PRP that contains several growth factors and cytokines may improve endometrial receptivity and implantation. PRP is collected from an autologous blood sample that has been enriched with platelets about 4-5 times more than circulating blood. PRP with a large amount of cytokines and growth factors can stimulate proliferation and regeneration. Recently, Chang reported the efficacy of PRP intrauterine infusion in endometrial growth in the refractory thin endometrium. Five participants in whom embryo transfer was canceled due to thin endometrium underwent intrauterine infusion of PRP. Adequate endometrial growth and pregnancy were reported in all of them and pregnancy was normally progressed in 4 women (13, 25-28).

Just recently, Reghini and co-workers suggested the efficacy of PRP for the treatment of inflammatory response in chronic degenerative endometritis in mares. In this trial, 13 mares with endometrium classified as chronic degenerative endometritis and 8 mares with normal endometrial histology were selected to investigate the PRP therapy effect. The mares were inseminated with fresh semen in two consecutive cycles in a crossover study design. Each mare served as its own control and the treatment was performed with intrauterine PRP infusion four hrs after artificial insemination. They concluded that PRP was effective in modulating the exacerbated uterine inflammatory response to semen in mares with chronic degenerative endometritis (29).

The result of our study revealed the efficacy of PRP intrauterine infusion on implantation and pregnancy. After PRP, 18 RIF patients were pregnant with 16 ongoing pregnancies and only one miscarriage and one molar pregnancy. Currently, PRP is safely used in several conditions in medicine. It is achieved from autologous blood sample and risks of immunological reaction and transmission of infections are eliminated. As we know, this is the first study that evaluated the efficacy of PRP intrauterine infusion in RIF patients and based on the results, it is suggested to design further randomized clinical trials in this field. According to several factors that involved in implantation process, we excluded a large number of women with a history of RIF in our trial and it was a limiting factor.

Conclusion

According to this study, it seems that PRP is effective in improvement of pregnancy outcome in RIF patients.
Acknowledgements

This present article is financially supported by Research Department of the School of Medicine Shahid Beheshti University of Medical Sciences. We especially thank Maryam Karimi, Elham Izadi, Mahnam Malakouti and Marjan Nasirzadeh for their great help and support to perform this study.

Conflict of Interest

None.

References

1. Coughlan C, Ledger W, Wang Q, Liu F, Demirrol A, Gurgan T, et al. Recurrent implantation failure: definition and management. Reprod Biomed Online 2014; 28: 14-38.
2. Simon A, Laufer N. Assessment and treatment of repeated implantation failure (RIF). J Assist Reprod Genet 2012; 29: 1227-1239.
3. El-Toukhy T, Taranissi M. Towards better quality international Journal of Reproductive Biomedicine Vol. 14. No. 10. pp: 625-628, October 2016.
4. Greco E, Bono S, Ruberti A, Lobascio AM, Greco P, Birick A, et al. Comparative genomic hybridization selection of blastocysts for repeated implantation failure treatment: a pilot study. BioMed Res Int 2014; 2014: 457913.
5. Salehpour S, Zamanian M, Saharkhiz N, Zadeh Gurgan T, et al. Recurrent implantation failure: standardizing its definition is the first step. Reprod Biomed Online 2006; 12: 383-385.
6. Greco E, Bono S, Ruberti A, Lobascio AM, Greco P, Birick A, et al. Comparative genomic hybridization selection of blastocysts for repeated implantation failure treatment: a pilot study. BioMed Res Int 2014; 2014: 457913.
7. Salehpour S, Zamanian M, Saharkhiz N, Zadeh Gurgan T, et al. Recurrent implantation failure: standardizing its definition is the first step. Reprod Biomed Online 2006; 12: 383-385.
8. Deceleer W, Osmanagaoglu K, Devroey P. The role of oxytocin antagonists in repeated implantation-failure. Facts Views Vis Obgyn 2012; 4: 227-229.
9. Margalioth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod 2006; 21: 3036-3043.
10. Green CJ, Fraser ST, Day ML. Insulin-like growth factor 1 increases apical fibronectin in blastocysts to increase blastocyst attachment to endometrial epithelial cells in vitro. Hum Reprod 2015; 30: 284-298.
11. Choi Y, Kim HR, Lim EJ, Park M, Yoon JA, Kim YS, et al. Integrative Analyses of Uterine Transcriptome and MicroRNAome Reveal Compromised LIF-STAT3 Signaling and Progesterone Response in the Endometrium of Patients with Recurrent/Repeate.
12. Katzorke N, Vilella F, Ruiz M, Krussel JS, Simon C. Diagnosis of Endometrial-Factor Infertility: Current Approaches and New Avenues for Research. Geburtshilfe Frauenheilkunde 2016; 76: 699-703.
13. Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, et al. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med 2015; 8: 1286-1290.
14. Garcia-Velasco JA, Acevedo B, Alvarez C, Alvarez M, Bellver J, Fontes J, et al. Strategies to manage refractory endometrium: state of the art in 2016. Reprod Biol Med Online 2016; 32: 474-489.
15. Rossi LA, Molina Romoli AR, Bertona Altieri BA, Burgos Flor JA, Scordo WE, Elizondo CM. Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial. Knee Surg Sports Traumatol Arthrosc 2016; 24: 185-199.
16. Ronci C, Ferraro AS, Lanti A, Missiroli F, Sinopoli S, Del Proposto G, et al. Platelet-rich plasma as treatment for persistent ocular epithelial defects. Transl Apher Sci 2015; 52: 300-304.
17. Sadabad BN, Behzadifar M, Arasteh F, Behzadifar M, Dehghan HR. Efficacy of Platelet-Rich Plasma versus Hylauronic Acid for treatment of Knee Osteoarthritis: A systematic review and meta-analysis. Electron Physic 2016; 8: 2115-2022.
18. Maria-Angeliki G, Alexandros-Efstratios K, Dimitris R, Konstantinos K. Platelet-Rich Plasma as a Potential Treatment for Noncicatricial Alopecias. Int J Trichol 2015; 7: 54-63.
19. Tejedor JC, Moro M, Merino JM, Gomez-Campdera MA, Garcia-del-Re M, A, A. Immunogenity and reactivity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis 2010; 27: 579-588.
20. Gat I, Levron J, Yerushalmi G, Dor J, Breugmaiz, Orietto R. Should zygotie intrafallopian transfer be offered to all patients with unexplained repeated in-vitro fertilization cycle failures? J Ovarian Res 2014; 7: 7.
21. Sak ME, Gul T, Evsen MS, Soydinc HE, Sak S, Ozler A, et al. Fibroblast growth factor-1 expression in the endometrium of patients with repeated implantation failure after in vitro fertilization. Eur Rev Med Pharmacol Sci 2013; 17: 399-402.
22. Karacan M, Ulug M, Arvas A, Cebi Z, Berberoglugi M, Batukan M, et al. Comparison of the transfer of equal numbers of blastocysts versus cleavage-stage embryos after repeated failure of in vitro fertilization cycles. J Assist Reprod Genet 2014; 31: 269-274.
23. Granot I, Gnainsky Y, Dekel N. Endometrial inflammation and effect on implantation improvement and pregnancy outcome. Reproduction 2012; 144: 681-686.
24. Wang H, Dey SK. Roadmap to embryo implantation: clues from mouse models. Nat Rev Genet 2006; 7: 185-199.
25. Yu W, Wang J, Yin J. Platelet-rich plasma: a promising product for treatment of peripheral nerve regeneration after nerve injury. Int J Neurosci 2011; 121: 176-180.
26. Borrione P, Gianfrancesco AD, Pereira MT, Pigozzi F. Platelet-rich plasma in muscle healing. Am J Phys Med Rehabil 2010; 89: 854-861.
27. Alcaraz J, Oliver A, Sanchez J, M. Platelet-Rich Plasma in a Patient with Cerebral Palsy. Am J Case Reports 2015; 16: 469-472.
28. Patel AN, Selzman CH, Kumpati GS, McKellar SH, Bull DA. Evaluation of autologous platelet-rich plasma for cardiac surgery: outcome analysis of 2000 patients. J Cardiothorac Surg 2016; 11: 62.
29. Reghini MF, Ramires Neto C, Segabinazzi LG, Castro Chaves MM, Dell'Aqua Cde P, Bussiere MC, et al. Inflammatory response in chronic degenerative endometritis mares treated with platelet-rich plasma. Theriogenology 2016; 86: 516-522.